BIOAGE Labs Inc

NASDAQ:BIOAUnited States

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

Contact Information

Headquarters

1445A South 50Th StreetRICHMOND, CA, United States 94804

Phone

510-806-1445

Fax

---

Executives

Independent Chairman of the Board

Jean-Pierre Garnier

President, Chief Executive Officer, Director

Kristen Fortney

Chief Financial Officer

Dov Goldstein

Chief Operating Officer, Director

Eric Morgen

Chief Medical Officer

Paul Rubin